This guideline covers the assessment, preparation, training and monitoring needed when using sedation in people aged under 19. It aims to help healthcare professionals decide when sedation is the most clinically and cost effective option for reducing pain and anxiety during operations for children and young people.
In October 2014, changes were made to the footnotes about the licensing of drugs to say that at the time of publication (December 2010), no drugs have a UK marketing authorisation specifically for sedation in all ages of infants, children and young people under 19, and to emphasise that prescribers should follow current summaries of product characteristics and seek advice if needed. In addition, appendix D was deleted.
This guideline includes recommendations on:
- pre-sedation assessment, communication, patient information and consent
- personnel and training
- sedation for painless imaging, painful procedures, dental procedures and endoscopy
- the clinical environment and monitoring during sedation
Who is it for?
- Healthcare professionals
- Commissioners and providers
- Under 19s who are having sedation and their families and carers
Is this guideline up to date?
We checked this guideline in December 2018. We found no new evidence that affects the recommendations in this guideline.
Guideline development process
This guideline was previously called sedation in children and young people: sedation for diagnostic and therapeutic procedures in children and young people.
The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian.
All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.
Local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.